Compare Coursera Inc (COUR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Moderna, Inc. — how do they compare? Coursera Inc trades at $5.65 (market cap $1.50B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 16.1× Coursera Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | MRNA | |
|---|---|---|
Market Cap | $1.50B | $24.18B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $81.80 |
52-Week Low | $5.09 | $22.36 |
Enterprise Value | $759.54M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.575, down 3.21% today, with a bearish technical signal and mixed earnings performance. Revenue growth continues with 2025 reaching $757.5M, though the company remains unprofitable with a -15.39% net margin. Recent Q2 2026 earnings beat expectations at $0.17 per share versus $0.10 expected. Analyst sentiment is positive with 53% buy ratings and a $7.70 consensus price target representing 38% upside potential.
The stock offers growth exposure to online education but faces profitability challenges. Upside catalysts include continued revenue expansion and strategic AI investments, while risks include persistent losses and competitive pressures. Wall Street sees significant undervaluation despite near-term headwinds.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
